March 17, 2026 4:56pm

Markets are staying up, following the ongoing struggle between oil pricing, econs, upcoming fed meeting results and the conflagration in the Middle East

What’s the goodwill gift by the U.S., who hopes to negotiate with Tehran for their people’s release; No Jaba here or is there?

RMi collects, curates, interprets and disseminates cell and gene therapy sector (C&GT) fact-based news, trustable and verified intel of share pricing data bridging the gap to an investment decision

Never leave a retail investor uninformed!  It’s not always time to buy or sell; but it is time to KNOW why!

I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others will not say or write about – facts in evidence!  I’m NOT at all writing a doom-and-gloom predictions as I am more frequently right than consequentially wrong; I am mostly EARLY in my prognostications!

RMi Research Note: Harvard Apparatus GT (OTCQB: HRGN): A new financing attempt, barely fulfills the need of a PPM raise … https://www.regmedinvestors.com/articles/13812

 

I chose to speak-up when many analysts, brokers and commentators have shut-up!

 

Tuesday: The Dow closed UP +47.40 points or +0.10%, the S&P closed UP +16.72 points or +0.25% while the Nasdaq closed UP +105.35 points or +0.47%

  • Theme of the session: Volatile oil prices and the fallout of the Iran war continue to influence investor sentiment

Tuesday’s (my) 40-company covered sector’s advance/decline line opened positive with 30 incliners, 8 decliners and 2 flats, ending with a positive close of 25 incliner, 14 decliners and 1 flat

  • The Russell 2000 index still raging

Henry’omics: We need to more than consider the macro-economic environment to comprehend the cause and effect of the macro versus micro data affecting “our” universe of cell and gene therapy (C&GT) sector

  • The U.S. dollar has enjoyed a reprieve in recent weeks, strengthening against all major currencies and once again regaining its place as a safe-haven asset in times of market stress.

The CBOE Fear (VIX) index, Tuesday closed at 22.38, after Monday’s 12.72, Friday’s 27.19, Thursday’s 27.27, Wednesday’s 24.31 and last Tuesday’s 25.46

Metrics: Tuesday …

  • The RUT was up +16.70 points or +0.94%,
  • The XLV was down -1.37 points or -0.91%,
  • The NBI was up +3.23 points or +0.06%;
  • The XBI was up +0.28 points or +0.23%
  • The IWM was up +1.58 or +0.64%;
  • The IBB was up +0.15 points or +0.09%,
  • The VIX was down -1.13 points or -4.81% at to 22.38

Q1/26 – March – 5 positive and 7 negative closes

  • February – 1 holiday, 8 negative and 11 positive sessions
  • January – 2 holidays, 2 neutral, 9 negative and 9 positive closes

 

Tuesday Closing UP (10 of 25) 

  • Alnylam Pharmaceuticals (ALNY +$4.32 after Monday’s +$5.50),
  • IQVA Holdings (IQV +$3.61),
  • CRISPR Therapeutics (CRSP +$1.67 after Monday’s -$0.33),
  • Alnylam Pharmaceuticals (ALNY +$1.51),
  • Lenz Therapeutics (LENZ +$0.76 after Monday’s -$0.41),
  • Agenus (AGEN +$0.70),
  • Capricor Therapeutics (CAPR +$0.63),
  • Moderna (MRNA +$0.62 after Monday’s +$0.75),
  • Supernus Therapeutics (SUPN +$0.61),
  • Dyne Therapeutics (DYN +$0.53),

Flat (1)

  • Generation Bio (GBIO) – acquired

Tuesday’s Closing DOWN (10 of 14): 

  • Vertex (VRTX -$3.61 after Monday’s -$3.24),
  • Voyager Therapeutics (VYGR -$0.40 after Monday’s -$0.135),
  • uniQure NV (QURE -$0.32 after Monday’s +$0.41),
  • Rocket Therapeutics (TCKT +$0.24),
  • Ultragenyx Pharmaceuticals (RARE -$0.22 after Monday’s +$0.48),
  • Entrada therapeutics (TRDA +$0.15),
  • Mesoblast (MESO +$0.15),
  • AxoGen (AXGN -$0.09 after Monday’s +$0.50),
  • Cellectis SA (CLLS -$0.05),
  • MiMedx MDXG -$0.05),
  • Harvard Apparatus RT (OTCQB: HRGN dropped in a.m. -$0.37 and closed down -$0.04 with 4,985 shares traded after barely trading lately) – Ponzi Scheme!
  • Fate Therapeutics (FATE -$0.03),
  • Ionis Pharmaceuticals (IONS -$0.01 after Monday’s +$1.15)

 

 

The Bottom Line: More of the … WHY

US stocks edged higher on Tuesday …

Crude oil prices climbed after renewed attacks in the Iran conflict

The jump in oil prices comes as the Fed begins a 2-day policy meeting.

  • Expectation holding interest rates steady
  • Rising fuel costs may complicate the inflation outlook, even as officials had recently signaled progress toward easing price pressures.

The Nasdaq added 0.5% holding support at its 200-day line after retaking it Monday. Small caps were off Tuesday's highs with the Russell 2000 rising 0.7%, and adding to Monday's 0.9% increase.

  • Volume was higher on the Nasdaq exchange and slightly lower on the NYSE versus Monday. On the Nasdaq exchange, rising stocks topped falling issues by around 5-to-3. On the NYSE, winners topped losers by around 8-to-3.

Some bad: Sliding share priccing ...

Eli Lilly (LLY) tumbled more than 6% after HSBC downgraded the drug stock to a rating of "reduce" from "hold" and slashed its price target to 850 from 1,070. Lilly stock was the biggest loser on the S&P 500 Tuesday.

  • Shares fell out of a flat base and now sit around 18% below their all-time high of 1,133.95, reached on Jan. 8. Lilly is deep below its 50-day moving average. Both it and the stock's relative strength lines are trending downward, showing weakness in shares.

 

Earnings release dates: soon to be catching up

  • Tuesday - 2/24 – AxoGen (AXGN), Beam Therapeutics (BEAM) and Supernus Therapeutics (SUPN)
  • Wednesday – 2/25 – MiMedx (MDXG), Ionis Pharmaceuticals (IONS) and Sarepta Therapeutics (SRPT)
  • Thursday – 2/26 – Rocket Pharmaceuticals (RCKT), Intellia Therapeutics (NTLA), Wave Life Sciences (WVE), Vericel (VCEL) and BioLife Solutions (BLFS)
  • Monday - 3/2 – Dyne Therapeutics (DYN)
  • Thursday – 3/5 – Regenxbio (RGNX), Compass therapeutics (CMPX)
  • Thursday – 3/12 – Capricor Therapeutics (CAPR)
  • Monday – 3/16 – Agenus (AGEN)
  • Wednesday – 3/25 – Precigen (PGEN)

 

RISK is always a factor remaining below the surface …  boiled-up as slight shocks of profiteering on upsides shook but not rocked the C&GT sector and markets!

  • As I had also written, cash is king for investors who want to keep some liquidity and avoid having to sell in a down market,

 

March – 3rd week

  • 3/17 - Tuesday closed positive with 25 incliners, 14 decliners and 1 flat
  • 3/16 - Monday closed positive with 27 incliners, 10 decliners and 3 flats

March – 2nd week

  • 3/13 – Friday closed negative with 11 incliner, 24 decliners and 5 flats
  • 3/12 – Thursday closed negative with 1 incliner, 36 decliners and 3 flats
  • 3/11 - Wednesday closed negative with 11 incliners, 26 decliners and 2 flats
  • 3/10 - Tuesday closed positive with 21 incliners, 16 decliners and 3 flats
  • 3/9 - Monday closed positive with 35 incliners, 2 decliners and 3 flats

March – 1st week

  • 3/6 - Friday closed negative with 14 incliners, 24 decliners and 2 flats
  • 3/5 – Thursday closed negative with 7 incliners, 32 decliners and 1 flat
  • 3 /4 – Wednesday closed positive with 32 incliners, 6 decliners and 2 flats
  • 3/3 - Tuesday closed negative with 2 incliners, 36 decliners and 2 flats
  • 3/2 - Monday closed negative with 15 incliners, 23 decliners and 3 flats

 

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there – closed end funds” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

 

Why do I keep repeating, framed in a different para, so investors can make the connection

The top three (3) performing in the session:    Winners

  • Tuesday: BioNTech (BNTX), IQIA Holdings (IQV) and CRISPR Therapeutics (CRSP0
  • Monday: Alnylam Pharmaceuticals (ALNY), Arrowhead Pharmaceuticals (ARWR) and Ionis Pharmaceuticals (IONS)
  • Last Friday: IQIA Holdings (IQV), and AxoGen (AXGN)

The worst three (3) in the session: Losers

  • Tuesday: Vertex (VRTX), Voyager Therapeutics (VYGR) and uniQure NV (QURE)
  • Monday: Vertex (VRTX), IQIA Holdings (IQV) and Wave Life Sciences (WVE)
  • Last Friday: Vertex (VRTX), Alnylam Pharmaceuticals (ALNY) and Capricor Therapeutics (CAPR)

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.